News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-Adhoc: Pulsion Medical Systems SE: MAQUET Medical Systems AG increases the amount of the cash compensation for the transfer of the shares in Pulsion Medical Systems SE to be EUR 20,67
EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare group PLC
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call
EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Humana’s 2026 Medicare Advantage Plans Prioritize Simplicity, Stability and Quality Care for Beneficiaries
Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced its Medicare Advantage and Medicare Prescription Drug Plan offerings for 2026. During the Medicare Annual Election
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) and reminds investors of the September
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc